Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cingulate Inc ( (CING) ) has shared an update.
At the 2025 Annual Meeting of Stockholders on June 10, Cingulate Inc.’s stockholders approved several proposals, including an amendment to the 2021 Omnibus Equity Incentive Plan to increase the number of shares by 800,000. The meeting also saw the election of a director, the ratification of KPMG LLP as the independent accounting firm, and the approval of a reverse stock split amendment, among other decisions. These approvals are expected to impact the company’s equity structure and governance, potentially affecting its market positioning and stakeholder interests.
The most recent analyst rating on (CING) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Cingulate Inc stock, see the CING Stock Forecast page.
Spark’s Take on CING Stock
According to Spark, TipRanks’ AI Analyst, CING is a Neutral.
Cingulate Inc.’s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, such as securing a grant and progress towards FDA approval, provide a positive outlook. The technical analysis shows neutral momentum, but valuation remains a concern due to financial losses and lack of dividends.
To see Spark’s full report on CING stock, click here.
More about Cingulate Inc
Average Trading Volume: 144,148
Technical Sentiment Signal: Hold
Current Market Cap: $21.02M
For an in-depth examination of CING stock, go to TipRanks’ Stock Analysis page.